
## Pascal Crépey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8067896/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adult Vaccination Strategies for the Control of Pertussis in the United States: An Economic Evaluation Including the Dynamic Population Effects. PLoS ONE, 2009, 4, e6284.	1.1	63
2	Epidemic variability in complex networks. Physical Review E, 2006, 73, 046131.	0.8	47
3	Detecting Robust Patterns in the Spread of Epidemics: A Case Study of Influenza in the United States and France. American Journal of Epidemiology, 2007, 166, 1244-1251.	1.6	46
4	A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 249-265.	0.7	46
5	A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. EClinicalMedicine, 2021, 38, 101001.	3.2	45
6	Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza and Other Respiratory Viruses, 2015, 9, 39-46.	1.5	40
7	Spread of hospital-acquired infections: A comparison of healthcare networks. PLoS Computational Biology, 2017, 13, e1005666.	1.5	39
8	Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value in Health, 2016, 19, 964-975.	0.1	31
9	A Conceptual Discussion About the Basic Reproduction Number of Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Settings. Clinical Infectious Diseases, 2021, 72, 141-143.	2.9	29
10	An ensemble model based on early predictors to forecast COVID-19 health care demand in France. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2103302119.	3.3	28
11	Drug sales data analysis for outbreak detection of infectious diseases: a systematic literature review. BMC Infectious Diseases, 2014, 14, 604.	1.3	23
12	Adherence and sustainability of interventions informing optimal control against the COVID-19 pandemic. Communications Medicine, 2021, 1, .	1.9	21
13	Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Human Vaccines and Immunotherapeutics, 2012, 8, 312-322.	1.4	20
14	Mathematical models of infection transmission in healthcare settings: recent advances from the use of network structured data. Current Opinion in Infectious Diseases, 2017, 30, 410-418.	1.3	19
15	Seasonal influenza vaccination coverage and its determinants among nursing homes personnel in western France. BMC Public Health, 2017, 17, 634.	1.2	17
16	From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. PLoS ONE, 2020, 15, e0233526.	1.1	14
17	2009 A(H1N1) Seroconversion Rates and Risk Factors among the General Population in Vientiane Capital, Laos. PLoS ONE, 2013, 8, e61909.	1.1	12
18	Quantitative Assessment of Preventive Behaviors in France during the Fukushima Nuclear Crisis. PLoS ONE. 2013. 8. e58385.	1.1	11

PASCAL CRéPEY

#	Article	IF	CITATIONS
19	SARS-CoV-2 transmission across age groups in France and implications for control. Nature Communications, 2021, 12, 6895.	5.8	11
20	A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom. Influenza and Other Respiratory Viruses, 2022, 16, 417-428.	1.5	10
21	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. Vaccines, 2022, 10, 479.	2.1	9
22	Assessing the role of inter-facility patient transfer in the spread of carbapenemase-producing Enterobacteriaceae: the case of France between 2012 and 2015. Scientific Reports, 2020, 10, 14910.	1.6	8
23	Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. BMC Public Health, 2020, 20, 1374.	1.2	8
24	Potential Impact of Influenza A/H1N1 Pandemic and Hand-Gels on Acute Diarrhea Epidemic in France. PLoS ONE, 2013, 8, e75226.	1.1	7
25	Increased incidence of acute parvovirus B19 infections in Marseille, France, in 2012 compared with the 2002–2011 period. Clinical Microbiology and Infection, 2014, 20, O176-O181.	2.8	7
26	Determinants of individuals' risks to 2009 pandemic influenza virus infection at household level amongst Djibouti city residents - A CoPanFlu cross-sectional study. Virology Journal, 2014, 11, 13.	1.4	7
27	Surveillance of gastrointestinal disease in France using drug sales data. Epidemics, 2014, 8, 1-8.	1.5	7
28	Compartmental models for seasonal hyperendemic bacterial meningitis in the African meningitis belt. Epidemiology and Infection, 2019, 147, e14.	1.0	7
29	Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. Value in Health, 2021, 24, 3-10.	0.1	6
30	Time-series modelling for the quantification of seasonality and forecasting antibiotic-resistant episodes: application to carbapenemase-producing Enterobacteriaceae episodes in France over 2010–20. Journal of Antimicrobial Chemotherapy, 2021, 76, 226-232.	1.3	4
31	Lockdown as a last resort option in case of COVID-19 epidemic rebound: a modelling study. Eurosurveillance, 2021, 26, .	3.9	3
32	Maternal Age at First Childbirth and Geographical Variation in Hepatitis B Virus Prevalence in Cameroon: Important Role of Mother-to-Child Transmission. Clinical Infectious Diseases, 2021, , .	2.9	3
33	Underestimation of Invasive Meningococcal Disease Case Fatality Rates. Clinical Infectious Diseases, 2009, 49, 1136-1137.	2.9	2
34	A cross-sectional study on infectious health risks regarding freshwater sports practice in Brittany, France. Journal of Water and Health, 2022, 20, 356-368.	1.1	1
35	Revisiting the primary bias: the role of innumeracy in the misperception of prevalence of chronic illnesses. Journal of Risk Research, 0, , 1-19.	1.4	1
36	Retrospective Public Health Impact of a Quadrivalent Influenza Vaccine in the United States Over the Period 2000-2014. Value in Health, 2014, 17, A664-A665.	0.1	0

Pascal Crépey

#	Article	IF	CITATIONS
37	Vaccin grippal haute dose: un vaccin adapté aux 65 ans et plus. La Presse Médicale Formation, 2022, 3, 105-105.	0.1	0
38	Title is missing!. , 2020, 15, e0233526.		0
39	Title is missing!. , 2020, 15, e0233526.		0
40	Title is missing!. , 2020, 15, e0233526.		0
41	Title is missing!. , 2020, 15, e0233526.		0
42	Title is missing!. , 2020, 15, e0233526.		0
43	Title is missing!. , 2020, 15, e0233526.		0